Gu et al. (2021) had reported a case of successful Osimertinib rechallenge after recovery from Osimertinib-induced ILD in a patient with EGFR-mutant non-small cell lung cancer, which experienced Grade2 ILD and recovered after glucocorticoid therapy for 13 days. Here, EGFR is linked to non-small cell lung carcinoma.